Company wished to develop a novel Phase I pain compound globally in the most commercially-viable initial indication and optimise subsequent launch sequence
Analysed current treatment pricing and reimbursement, development pipeline, as well as real-world evidence around unmet need and treatments patterns in over 10 different possible indications to determine initial indication with greatest value. Validated assumptions with external payers, KOLs, and regulatory bodies, as well as internal experts. Recommended life-cycle management opportunities post initial launch
Obtained buy-in from internal stakeholders across regions and aligned organisation around the lead indication and optimal development pathway
Company considering acquiring the rights to a new treatment for a rare disease with little experience in value-based pricing and health economics
Reviewed disease area literature to understand quality of life and costs, benefit of treatment, as well as market share and revenue forecasts. Developed an integrated value assessment model (VAM) that allowed the team to test changes in the target product profile and pricing methodology on the overall value
Provided a clear understanding of the direct impact on financial value from changes to product characteristics, as well as the ability to run sensitivity analysis around key uncertainties/scenarios
Social Media Mining
Company interested in generating potential indications of unmet need for repurposing of an existing compound
Brainstormed potential data sources, arriving at social media given its efficiency in collection, analysis and untapped potential. Mined social media data for positive sentiments of the compound alongside mentions of organs/body parts and positive effects not within current licensed indications
Provided a list of possible indications to explore with further analysis and studies